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Abstract
Nanoparticles are employed for delivering therapeutics into cells1,2. However, size, shape, surface
chemistry and the presentation of targeting ligands on the surface of nanoparticles can affect
circulation half-life and biodistribution, cell specific internalization, excretion, toxicity, and
efficacy3-7. A variety of materials have been explored for delivering small interfering RNAs
(siRNAs) - a therapeutic agent that suppresses the expression of targeted genes8,9. However,
conventional delivery nanoparticles such as liposomes and polymeric systems are heterogeneous
in size, composition and surface chemistry, and this can lead to suboptimal performance, lack of
tissue specificity and potential toxicity10-12. Here, we show that self-assembled DNA tetrahedral
nanoparticles with a well-defined size can deliver siRNAs into cells and silence target genes in
tumours. Monodisperse nanoparticles are prepared through the self-assembly of complementary
DNA strands. Because the DNA strands are easily programmable, the size of the nanoparticles and
the spatial orientation and density of cancer targeting ligands (such as peptides and folate) on the
nanoparticle surface can be precisely controlled. We show that at least three folate molecules per
nanoparticle is required for optimal delivery of the siRNAs into cells and, gene silencing occurs
only when the ligands are in the appropriate spatial orientation. In vivo, these nanoparticles
showed a longer blood circulation time (t1/2 ∼ 24.2 min) than the parent siRNA (t1/2 ∼ 6 min).
*Correspondence and requests for materials should be addressed to D.G.A. (dgander@mit.edu).
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tPreviously, self-assembled three-dimensional structures of short oligonucleotides have been
explored for imaging and delivery applications13-15. In this study, we prepared
oligonucleotide nanoparticles (ONPs) by programmable self-assembly of short DNA
fragments and therapeutic siRNAs to develop a population of molecularly identical
nanoparticles with controllable particle size and target ligand location and density. As shown
in Fig. 1a, six DNA strands with complementary-overhangs at the 3′ ends can self-assemble
into a tetrahedron consisting of 186 Watson-Crick base pairs. The six edges are 30 base
pairs in length and the theoretical tetrahedron height is approximately 8 nm with 10 nm
edges. Each edge contains a nick in the middle where the 5′ and 3′ ends of an
oligonucleotide meet. The overhang at this nick is complementary to the overhang of siRNA
strands. Thus six siRNAs are bound per nanoparticle (1 per each edge). Chemically
modified siRNA with 2′-OMe modifications shown to significantly enhance serum stability
as well as reduce immune stimulation potential was used in these experiments16. Native
polyacrylamide gel electrophoresis (PAGE) analysis shows the step-wise assembly of DNA
tetrahedron particles as each strand is added. A distinct band shift was observed indicating
DNA assembly and yields over 95% and 98% were observed for tetrahedron formation and
siRNA hybridization respectively (Fig. 1b). The tetrahedron structure was imaged by AFM
in aqueous buffer and high-resolution images confirmed the presence of the three upper
edges of individual tetrahedron as well as a height of ∼ 7.5 nm (Fig. 1c). Dynamic light
scattering measured a hydrodynamic diameter of ∼28.6 nm with a narrow size distribution,
even when ONPs were prepared at a high concentration (8 μM) (Supplementary Fig. 1).
It has been suggested that the optimal particle size for a cancer targeting nanodelivery
carrier is 20–100 nm3,4,17. Nanoparticles with a diameter above 20 nm avoid renal
clearance, which is a typical occurrence for monomeric siRNA, and enhance delivery to
certain tumour types through the enhanced permeability and retention effect (EPR)18,19. In
theory, ONPs are large enough to avoid renal filtration (>20 nm) but small enough to
penetrate through the leaky vasculatures in a tumour region, bind to cell surface receptors,
and facilitate intracellular uptake, while reducing reticuloendothelial system (RES)-mediated
clearance. Because the ONPs are molecularly defined, they exist as a single uniform
population in terms of size and shape. This is distinctly different from traditional cationic
delivery carriers that can exist in a range of shapes and sizes. The nucleic acid composition
of the ONPs allows precise spatial control of all decorating ligands via hybridization and
means that the siRNA component of the particle can be varied.
To ascertain whether ONPs can provide effective targeted delivery of siRNA to human
cancer cells, we conjugated various cancer-targeting ligands from peptides to small
molecules. It is hypothesized that intracellular delivery of the ONPs will be promoted by
active targeting of specific surface receptors on cancer cells20,21. Among the 28 different
targeting ligands tested here, folic acid (FA) conjugated ONPs exhibited the greatest gene
silencing, over 50 % reduction of firefly luciferase expression in Hela cells in a dose-
dependent manner (Fig. 2a). A few cationic peptides (Hph-1 and Penetratin) also showed the
reduction of firefly luciferase expression, however the structures of the ONPs modified with
these ligands were less stable causing unwanted aggregation due to the charge interaction
between the cationic peptides and anionic nucleic acids. For folate-mediated gene silencing,
folate receptor overexpressing KB cells (expressing green fluorescent protein (GFP)) were
also tested to confirm specificity of targeted gene silencing. Our data showed over 60 %
reduction of GFP expression in KB cells at a 35 nM dose of FA conjugated ONPs carrying
siRNA targeting GFP (Supplement Fig. 2).
In addition to optimal particle size and cancer specificity for intracellular siRNA delivery,
ONPs allow full control of spatial orientation of ligands as well as the density of ligands on
the nanoparticle surface. Since the geometry of the ONPs is well defined, it is possible to
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tinvestigate correlations of ligand density and orientation with gene silencing. To evaluate
the importance of spatial orientation for the targeting ligand, six different overhang
sequences were designed for siRNA hybridization and the number of hybridized siRNAs
was varied as well as the density and location of the folate. We can specifically control the
number of siRNAs on the core DNA tetrahedron from one to six (Supplement Fig. 3). By
using both folic acid conjugated and non-conjugated siRNAs, the level of GFP gene
silencing was investigated with various numbers of folate ligands, while maintaining the
same number of siRNAs on each nanoparticle (Fig. 2b). Our results indicate that minimum
of three folate ligands are required to achieve GFP gene silencing. Interestingly, more than
three ligands on one particle did not improve the gene silencing efficiency. Importantly, the
orientation/location of the ligands dramatically affected the gene silencing (Fig. 2c). When
three folic acids are decorated on the tetrahedron such that the local density is maximized
(three folate encompass a face or vertex of the tetrahedron: example location 1, 2, 3a or 1, 2,
3c in Fig. 2c, respectively), GFP silencing was observed. However, when three folic acids
were located with greater distance from each other on the tetrahedron, such that the local
density is lower (locations 1, 2, 3b), we did not observe any GFP silencing. Interestingly,
our confocal study revealed that the intracellular uptake of these nanoparticles were similar,
regardless of folic acid location, however potent gene silencing activity was only observed
for nanoparticles with the appropriate spatial orientation of folic acid (Fig. 2d). It is
conceivable that, with a specific orientation of FA, the higher local ligand density may
influence the intracellular trafficking pathway of nanoparticles through the cells and
corresponding gene silencing. Although it is believed that the density and location of ligands
can greatly influence the nanoparticle/cell membrane interactions as well as the intracellular
uptake pathways, this phenomenon is extremely difficult to prove by conventional
nanoparticles due to the lack of precise control of ligand density and orientation on a single
nanoparticle22,23. To our knowledge, this is the first in vitro evaluation of ligand density and
orientation that can alter the function of a nanoparticle-delivery system.
To verify in vivo delivery of ONPs, the pharmacokinetic (PK) profile and organ bio-
distribution were investigated in nude mice bearing KB xenograft tumours. Cy5-labeled
ONPs with folate ligands (3 nmol of siRNA, ∼ 2.0 mg/kg) (6 FA ligands per ONP) were
systemically delivered via tail-vein injection and the in vivo behavior was quantitatively
measured over the course of 24 h by fluorescence molecular tomography fused with
computed tomography (FMT-CT)24,25. Co-registration of FMT and CT provided high-
resolution fluorescence images of the tumour targeting by ONPs and the distribution of
nanoparticles in five major organs. As shown in Fig. 3a, ONPs primarily accumulated in
tumour and kidney, with little accumulation in other organs such as liver, spleen, lung, and
heart. Ex vivo fluorescence images at 12 h post-injection also correspond well with the
biodistribution data. A reconstructed 3D FMT-CT image of a tumour bearing mouse
revealed the accumulation of ONPs in the tumour region as early as 25 min post-injection
(Fig. 3b). In addition, the blood half-life data indicated that ONPs have a longer blood
circulation time (t1/2 ∼ 24.2 min) compared to the parent siRNA (t1/2 ∼ 6 min)
(Supplementary Fig. 4)26.
In order to assess the therapeutic potential of ONPs as cationic-free gene delivery carriers,
we conducted in vivo gene silencing of firefly luciferase expressing KB xenografts. Folic
acid conjugated ONPs with anti-luciferase siRNA were administrated at a dose of 2.5 mg/kg
of siRNA into mice either by tail-vein injection or intra-tumour injection. Silencing was
evaluated 48 h post-injection by measuring bioluminescent intensity in the tumour, (Fig. 3c).
Both tail vein and intra-tumour injections resulted in approximately 60 % decrease in
bioluminescent intensity. When mice were injected in either mode of administration with
folic acid conjugated anti-luciferase siRNAs (not assembled into nanoparticles), no decrease
in bioluminescent intensity was observed. This result corresponds well with our in vitro
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tsilencing experiment, confirming that the ONPs are a critical factor for successful gene
silencing. In addition, measurement of the firefly luciferase mRNA level in tumour cells
strongly supported the target specific mRNA cleavage by both systemic and local delivery
of ONPs (Fig. 3d). A dose dependent study revealed that tumour specific accumulation of
ONPs was achieved by systemic delivery (Fig 3e) and the IC50 for luciferase silencing was
estimated to be approximately 1.8 mg/kg (Supplementary Fig. 5a). Finally, the immune
response of ONPs was monitored by measuring the IFN-α levels in blood samples 6 h post-
injection and there was no significant increase in IFN-α as compared to levels in untreated
mice (Supplementary Fig. 5b).
This study has demonstrated that six single-stranded DNA fragments, and six double-
stranded siRNAs, can self-assemble in a one-step reaction to generate DNA/siRNA
tetrahedral nanoparticles for targeted in vivo delivery. The overhang design on the DNA
strands allowed specific hybridization of complementary siRNA sequences, and provided
full control over spatial orientation of siRNA and the locations and density of cancer
targeting ligands. The ONPs can be modified with different tumour targeting ligands by
simple conjugation chemistry, extending the use of these nanoparticles for the treatment of
various cancers. We observed robust gene silencing via both intra-tumour and systemic
injection of ONPs in KB xenograft tumours without any detectable immune response. We
believe these particles may also have utility in the treatment of other tissues through
modification of size and ligand type.
Method Summary
Preparation of self-assembled DNA/siRNA nanoparticles (ONPs)
Six single-stranded DNAs from IDT (Chicago, IL) and 6 double strand siRNAs from
Alnylam (Cambridge, MA) were annealed to prepare ONPs. DNA strands (final strand
concentration 3.3 μM each) were mixed in equal molar ratio in annealing buffer containing 5
mM Mg2+ and a 6-fold molar excess of siRNA strands were added to the solution. The
solution was heated to 90°C for 2 min and rapidly cooled to 4°C to generate ONPs (3.3 μM
particle concentration). For folic acid conjugated ONPs, folic acid conjugated luciferase or
GFP siRNA (Alnylam) were used. All siRNAs were chemically modified with site-specific
2′-OMe chemistry to avoid immune response activation and to improve nuclease
resistance26.
In vitro testing of ONPs
HeLa cells, modified to stably express both firefly and Renilla luciferase genes, were
utilized for in vitro screening of ONPs. ONPs with different ligands were applied to 1.5 ×
104 HeLa cells in medium containing serum. Firefly luciferase silencing was assessed 24 h
post-transfection using a Dual-Glo Luciferase Assay kit (Promega, Madison, WI).
Transfections were performed in quadruplicate. siRNA transfected into cells using
Lipofectamine RNAiMax (Invitrogen) was used as a positive control (Fig. 2). For folate
receptor targeted GFP gene silencing, GFP expressing KB cells were used. The level of GFP
silencing was evaluated at 24 h post-transfection using a BD FACSCalibur (Franklin Lakes,
NJ).
siRNA delivery in mice using ONPs
All animal experiments were conducted using institutionally approved protocols. Luc-KB
tumour bearing female BALB/c nude mice (Charles River Laboratories, Wilmington, MA)
received tail vein or intra-tumoural injections of either PBS (negative control) or ONPs
containing anti-Luc siRNA diluted in PBS (n=7 per each group, siRNA
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tconcentration=2.5mg/kg). Two days post-injection, bioluminescence intensity (BLI) in KB
tumours was measured by a IVIS Lumina imaging system (Hopkinton, MA).
Full Methods and any associated references are available in the online version of the paper
at www.nature.com/naturenanotechnology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Programmable self-assembly of oligonucleotide nanoparticles
a, Schematic of DNA strands for tetrahedron formation (arrow head represents 5′ end of the
nucleic acid strand and each colour corresponds to one of the six edges of the tetrahedron)
and representation showing site-specific hybridization of siRNA to the self-assembled
nanoparticles. b, Native PAGE analysis to verify self-assembly of DNA tetrahedron and
hybridization of siRNAs to DNA core, with the presumed structures schematically drawn to
the right of the gel (Lane 1: strand 1; Lane 2: strand 1 and strand 2; Lane 3: strands 1–3;
Lane 4: strands 1–4; Lane 5: strands 1–5; Lane 6: strands 1–6; Lane 7: strands 1–6 and
siRNAs). C, AFM image showing mono-disperse tetrahedron nanoparticles on mica. Inset
indicates AFM images recorded with an ultra-sharp tip resolving the three upper edges of
tetrahedral.
Lee et al. Page 7
Nat Nanotechnol. Author manuscript; available in PMC 2014 January 22.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 2. In vitro screening and gene silencing using ONPs
a, Screening of tumour-targeting ligands using ONPs in a luciferase silencing assay in HeLa
cells (Control: ONPs without targeting ligands, LF: Lipofectamine RNAiMax, peptide
abbreviations are described in supplementary information). b, GFP gene silencing efficiency
varies with folic acid (FA) density on ONPs (n=4, siRNA concentration=35 nM). *p<0.003,
**p<0.001 as compared with the control; ns=not significant. c, The structure and function
relationship of the orientation of ligand (bullet shapes on end of siRNA strands) and the
efficiency of gene silencing for ONPs (n=4, siRNA concentration=35 nM, set A: FA on 1, 2,
and 3a; set B: FA on 1, 2, and 3b; set C: FA on 1, 2, and 3c). *p<0.018 **p<0.019 as
compared with the control; ns=not significant. d, Automated confocal analysis of
intracellular uptake of ONPs with different FA orientations (n=8).
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In vivo PK and gene silencing in tumour xenograft mouse model. a, PK of ONPs in KB
tumour-bearing mice and ex vivo fluorescence image of five major organs and tumour at 12h
post-injection (T: Tumour, Lv: Liver, S: Spleen, K: Kidney, Lu: Lung, H: Heart). High level
of siRNA accumulation occurs in tumor tissue. b, Tumour specific accumulation of ONPs as
determined by FMT-CT after 25 min post-injection (left: CT scan, right: 3D FMT-CT).
Circular region indicates the location of tumour xenograft. Warmer colour in tumour region
represents the site-specific accumulation of Cy5 labeled ONPs. c, In vivo luciferase
silencing in KB tumour xenografts (n=7, BLI: Bioluminescence Intensity, Control: PBS
injection, IT: intratumoural, IV: intravenous, ONPLuc: ONPs with Folate conjugated anti-
luciferase siRNA, siLuc: Folate conjugated anti-luciferase siRNA). siRNA
concentration=2.5mg/kg. *p<0.138, **p<0.002 as compared with the control, ns=not
significant. Four Image boxes shown above the bar graph represent the live BLI image of
mice from each group. Warmer colour indicates strong BLI in tumour xenografts. d,
Quantitative analysis of luciferase mRNA degradation in KB tumours 2 days after ONP
injection (n=3, Luc: Firefly luciferase gene, ONPGFP: ONPs with Folate conjugated anti-
GFP siRNA). siRNA concentration=2.5mg/kg. GAPDH is used as house keeping gene.
Luciferase mRNA level is expressed as a ratio to GAPDH (Luc/GAPDH). *p<0.05,
**p<0.03 as compared with the control, ns=not significant. e, In vivo live fluorescence
images showing dose responsive accumulation of ONPs in KB tumours compared to folic
acid conjugated siRNA (siRNA alone); animals were treated by systemic injection (n=3) and
images are representative of each group.
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